Rakovina signs new deal with Variational AI

Executive Summary

• Rakovina Therapeutics and Variational AI have expanded their existing collaboration to accelerate the lead optimization of Rakovina’s kt-5000 series of ATR inhibitors using Variational AI’s Enki generative AI platform.
• The expanded agreement focuses on iteratively optimizing initial leads to identify a clinical candidate in months rather than years, with Variational AI generating compound designs and Rakovina retaining full control over advancement into laboratory testing.
• This initiative aims to reduce the time and cost of early-stage drug discovery for ATR inhibitors, a promising therapeutic strategy for solid tumors including ovarian, breast, and prostate cancers.

Key Details

• Expanded Agreement: The collaboration now focuses on lead optimization of drug candidates identified by Variational AI's Enki platform and selected by Rakovina for the kt-5000 ATR inhibitor program.
• Technology Application: Variational AI will use its generative AI platform to generate and prioritize multiple optimized compound designs, aiming to identify a clinical candidate in months instead of the industry standard of years.
• Operational Control: Rakovina retains full control over which candidates are advanced into laboratory testing and further development.
• Target Profile: The kt-5000 program consists of small-molecule inhibitors targeting ATR (ataxia telangiectasia and Rad3-related), a regulator of the DNA damage response that helps cancer cells survive replication stress.
• Therapeutic Indications: ATR inhibition is being pursued for solid tumors, specifically cancers with DNA repair deficiencies such as ovarian, breast, and prostate cancer.
• Recent Preclinical Data: Rakovina recently reported preclinical findings for the kt-5000 series, including compounds with dual ATR/mTOR activity designed to achieve central nervous system (CNS) penetration, presented at the Society for Neuro-Oncology annual meeting.
• Strategic Goals: The collaboration seeks to address known limitations of existing ATR inhibitors and optimize for potency, selectivity, and CNS penetration to create a more efficient path to human trials.

Notable Quotes

• Jeffrey Bacha, Executive Chairman, Rakovina Therapeutics: "ATR is a proven oncology target, but real differentiation comes from optimizing the drug itself... This expanded collaboration with Variational AI enables a highly focused, AI-driven refinement of kt-5000 compounds identified for further evaluation, with particular attention to potency, selectivity and CNS penetration. The result is a more efficient path to identifying high-quality candidates while maintaining strategic flexibility for development and partnering."
• Handol Kim, Co-founder and CEO, Variational AI: "Our Enki generative AI platform efficiently explores novel chemical space and has already generated promising leads for Rakovina... With this expanded collaboration, we are now applying Enki to exploit these novel leads through local chemical search to efficiently perform lead optimization and enable Rakovina to get to human trials faster."